Intervention: GCAR1, an autologous, lentivirally transduced chimeric antigen receptor T‑cell (CAR‑T) therapy. Mechanism: the patient’s T lymphocytes are engineered to express a CAR that recognizes glycoprotein non‑metastatic B (GPNMB) on tumor cells, leading to CAR‑mediated T‑cell activation and cytotoxic killing of GPNMB‑expressing cells. Drug type: biological cell therapy (immunotherapy/CAR‑T). Targets: GPNMB‑positive alveolar soft part sarcoma cells, engages T‑cell effector pathways to attack the tumor. Single‑patient, Early Phase 1.